Peter Kinyanjui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Peter Kinyanjui has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Andre Trollip
Fdn Innovat New Diagnost FIND South Africa, Cape Town, South Africa
1 shared publication - Andrew Whitelaw
Affiliations Division of Medical Microbiology and Immunology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa, National Health Laboratory Service, Tygerberg Hospital, Cape Town, South Africa
1 shared publication - Atunga Nyachieo
Kenya Institute of Primate Research, Nairobi, Kenya, Kenya
1 shared publication - Dawit A. Wendifraw
Ethiopian Publ Hlth Inst, Natl Clin Bacteriol & Mycol Reference Lab, Addis Ababa, Ethiopia
1 shared publication - Francis Kariuki
Department of Biochemistry, University of Nairobi, Nairobi, Kenya
1 shared publication Gerald Juma
Department of Biochemistry, University of Nairobi, Nairobi, Kenya
1 shared publication
Latest Publications
- Open Access
- 31 January 2022
- Published by AOSIS in African Journal of Laboratory Medicine
- Vol. 11 (1) , 1476
Implementation of a customised antimicrobial resistance laboratory scorecard in Cameroon, Ethiopia and Kenya
Background: In low-resource settings, antimicrobial resistance (AMR) is detected by traditional culture-based methods and ensuring the quality of such services is a challenge. The AMR Scorecard provides laboratories with a technical assessment tool for strengthening the quality of bacterial culture, identification, and antimicrobial testing procedures.Objective: To evaluate the performance of the AMR Scorecard in 11 pilot laboratory evaluations in three countries also assessed with the Stepwise Laboratory Quality Improvement Process Towards Accreditation (SLIPTA) checklist.Methods: Pilot laboratory evaluations were conducted in Cameroon, Ethiopia and Kenya between February 2019 and March 2019. Assessors with previous SLIPTA and microbiology experience were trained. Assessors performed the laboratory assessments using the SLIPTA and AMR Scorecard tools.Results: Weaknesses in technical procedures and the quality management systems were identified in all areas and all laboratories. Safety had the highest mean performance score (SLIPTA: 68%; AMR Scorecard: 73%) while management review had the lowest (SLIPTA: 32%; AMR Scorecard: 8%) across all laboratories. The AMR Scorecard scores were generally consistent with SLIPTA scores. The AMR Scorecard identified technical weaknesses in AMR testing, and SLIPTA identified weaknesses in the quality management systems in the laboratories.Conclusion: Since the AMR Scorecard identified important gaps in AMR testing not detected by SLIPTA, it is recommended that microbiology laboratories use SLIPTA and the AMR Scorecard in parallel when preparing for accreditation. Expanding the use of the AMR Scorecard is a priority to address the need for quality clinical microbiology laboratory services in support of optimal patient care and AMR surveillance.
- 31 January 2022
- Published by AOSIS in African Journal of Laboratory Medicine
- Vol. 11 (1) , 1476
Open AccessImplementation of a customised antimicrobial resistance laboratory scorecard in Cameroon, Ethiopia and Kenya
Background: In low-resource settings, antimicrobial resistance (AMR) is detected by traditional culture-based methods and ensuring the quality of such services is a challenge. The AMR Scorecard provides laboratories with a technical assessment tool for strengthening the quality of bacterial culture, identification, and antimicrobial testing procedures.Objective: To evaluate the performance of the AMR Scorecard in 11 pilot laboratory evaluations in three countries also assessed with the Stepwise Laboratory Quality Improvement Process Towards Accreditation (SLIPTA) checklist.Methods: Pilot laboratory evaluations were conducted in Cameroon, Ethiopia and Kenya between February 2019 and March 2019. Assessors with previous SLIPTA and microbiology experience were trained. Assessors performed the laboratory assessments using the SLIPTA and AMR Scorecard tools.Results: Weaknesses in technical procedures and the quality management systems were identified in all areas and all laboratories. Safety had the highest mean performance score (SLIPTA: 68%; AMR Scorecard: 73%) while management review had the lowest (SLIPTA: 32%; AMR Scorecard: 8%) across all laboratories. The AMR Scorecard scores were generally consistent with SLIPTA scores. The AMR Scorecard identified technical weaknesses in AMR testing, and SLIPTA identified weaknesses in the quality management systems in the laboratories.Conclusion: Since the AMR Scorecard identified important gaps in AMR testing not detected by SLIPTA, it is recommended that microbiology laboratories use SLIPTA and the AMR Scorecard in parallel when preparing for accreditation. Expanding the use of the AMR Scorecard is a priority to address the need for quality clinical microbiology laboratory services in support of optimal patient care and AMR surveillance.
- 18 December 2021
- Published by Springer Nature in Archives of Microbiology
- Vol. 204 (1) , 1-7
Evaluation of the detection of staA, viaB and sopE genes in Salmonella spp. using the polymerase chain reaction (PCR)
Typhoid fever is caused by the bacteria Salmonella enterica subspecies enterica serovar Typhi (S. Typhi) and remains a significant health problem in many developing countries. Lack of adequate diagnostic capabilities has contributed greatly in making typhoid fever endemic in these regions. Reliable and inexpensive diagnostic tests are needed to improve the management of this disease burden. We evaluated the ability of staA, viaB and sopE genes to detect and differentiate between the three most prevalent Salmonella spp. in Kenya (S. Typhi, S. Typhimurium and S. Enteritidis) using conventional polymerase chain reaction (PCR). The staA primers and viaB primers were found to be specific only for the different strains of S. Typhi, producing PCR products of 585 bp and 540 bp, respectively. The sopE primers was demonstrated to be specific for all Salmonella spp. producing a 465 bp PCR product with no amplification with E. coli and S. boydii bacterial strains.
- 18 December 2021
- Published by Springer Nature in Archives of Microbiology
- Vol. 204 (1) , 1-7
Evaluation of the detection of staA, viaB and sopE genes in Salmonella spp. using the polymerase chain reaction (PCR)
Typhoid fever is caused by the bacteria Salmonella enterica subspecies enterica serovar Typhi (S. Typhi) and remains a significant health problem in many developing countries. Lack of adequate diagnostic capabilities has contributed greatly in making typhoid fever endemic in these regions. Reliable and inexpensive diagnostic tests are needed to improve the management of this disease burden. We evaluated the ability of staA, viaB and sopE genes to detect and differentiate between the three most prevalent Salmonella spp. in Kenya (S. Typhi, S. Typhimurium and S. Enteritidis) using conventional polymerase chain reaction (PCR). The staA primers and viaB primers were found to be specific only for the different strains of S. Typhi, producing PCR products of 585 bp and 540 bp, respectively. The sopE primers was demonstrated to be specific for all Salmonella spp. producing a 465 bp PCR product with no amplification with E. coli and S. boydii bacterial strains.